Gubra (GUBRA.CO) Stock Analysis & AI Equity Report
Gubra (GUBRA.CO) overview
Gubra (GUBRA.CO) stock analysis and AI equity research. For the latest completed financial year, 2024, Gubra reported revenue of DKK 266m and operating profit of DKK -50.0m; the year-end share price was N/A and market capitalisation was N/A. Gubra is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Gubra's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-06-15. Data will be refreshed during report generation.
About Gubra
Gubra A/S is a Danish biotechnology company focused on peptide-based drug discovery and preclinical research services. It operates through Biotech, CRO Services and Ventures, developing proprietary therapeutic programs and providing contract research for partners. The company’s value drivers are early-stage drug discovery, scientific data generation and collaboration with external clients and licensees.
Generate the Gubra report
Gubra is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Gubra and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.